Esperion shareholders approve 6.25M share increase to 2022 stock plan and 6.175M increase to ESPP

Esperion Therapeutics, Inc.

Stockholders re-elected directors Antonio M. Gotto Jr. and Nicole Vitullo with 87.9M and 91.0M votes for, respectively.
Advisory say-on-pay proposal approved with 70.7M votes (74% of votes cast).
Ratification of Ernst & Young as auditor for FY2024 approved with 136.8M votes (98.3% of votes cast).
Amendment to 2022 Stock Option Plan increasing authorized shares by 6,250,000 approved with 88.1M votes.
Amendment to 2020 ESPP increasing reserved shares by 6,175,000 approved with 88.8M votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.